Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aclaris Therapts (NQ: ACRS )

8.700 +0.350 (+4.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aclaris Therapts

< Previous 1 2 Next >
Aclaris Therapeutics Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Aclaris Therapeutics's Earnings Outlook
 
Via Benzinga
3 Biotech Stocks to Sell Before They’re 6 Feet Under
Biotech stocks with no earnings, no cash, and no path to profit will have no chance at survival. Here's three such biotech stocks to avoid. 
Via InvestorPlace
(ACRS) - Analyzing Aclaris Therapeutics's Short Interest
 
Via Benzinga
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
 
Via Benzinga
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Analyst Ratings for Aclaris Therapeutics
 
Via Benzinga
Why Aclaris Therapeutics Is Crashing Today
The company announced disappointing results from a phase 2a clinical study. 
Via The Motley Fool
Why Aclaris Therapeutics Stock Is Plunging Today
 
Via Benzinga
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the... 
Via Benzinga
DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday
Wells Fargo cut the price target for Cheniere Energy, Inc. (NYSE: LNG) from $236 to $230. Wells Fargo analyst Michael Blum maintained an Overweight rating. Cheniere Energy shares fell 4.8% to close at... 
Via Benzinga
Aclaris Therapeutics's Return On Capital Employed Insights
 
Via Benzinga
Looking Into Aclaris Therapeutics's Return On Capital Employed
 
Via Benzinga
Looking Into Aclaris Therapeutics Return On Capital Employed
  
Via Benzinga
These 2 Biotech Stocks Made Big Monday Moves
Find out which was the winner and which was the loser. 
Via The Motley Fool
Nasdaq Rises 50 Points; Ciena Earnings Top Expectations
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P... 
Via Benzinga
As Focus Shifts From Hidradenitis Suppurativa, Analyst Seems Bullish On Aclaris
Aclaris Therapeutics Inc (NASDAQ: ACRS) flunked a 12-week, Phase 2a study of zunsemetinib (ATI-450) for moderate to severe hidradenitis suppurativa. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 36 companies set new 52-week lows. 
Via Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500... 
Via Benzinga
Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Week In Review: Full-Life Acquires Focus-X And Its Eight Radiotherapeutics In $245 Million Deal
Full-Life Technologies, a Brussels-Shanghai radiotherapeutics company, will acquire Focus-X Therapeutics for up to $245 million. Using its proprietary peptide engineering technology, Focus-X has built... 
Via Talk Markets
10 Best Stocks to Buy Now in December
These beaten-down stocks have significant upside. 
Via The Motley Fool
Aclaris Therapeutics: Q2 Earnings Insights
  Aclaris Therapeutics (NASDAQ:ACRS) reported its Q2 earnings results on Wednesday, August 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
 
Via Benzinga
Aclaris Therapeutics's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Aclaris Therapeutics's (NASDAQ:ACRS) reported sales totaled $1.45 million. Despite a 17.61% increase in earnings, the company posted a loss of $18.79... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
Upgrades 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.